公开(公告)号：US20240287138A1

公开(公告)日：2024-08-29

申请号：US18429587

申请日：2024-02-01

申请人： Merck Sharp & Dohme LLC

发明人： Kaustav Biswas ,  Nicolas C. Boyer ,  Brandon D. Cash ,  Fa-Xiang Ding ,  John R. Frost ,  Michael B. Garrigou ,  James P. Jewell ,  Ahmet Kekec ,  Hu-Jung Julie Lee ,  Songnian Lin ,  Ashwin U. Rao ,  Daniel J. Sindhikara ,  Murray Wan ,  Yuping Zhu ,  Susan L. Zultanski ,  Tony Siu ,  Andrew M. Haidle ,  Claudio Mapelli ,  Luca Gambini ,  Federica Orvieto ,  Roberta Tozzi ,  Nicolo Maria Pasquini ,  Luigi Abate ,  Giordano Proietti ,  Michael Wuo ,  Ryan Chau

IPC分类号： C07K7/54 ,  A61P29/00

CPC分类号： C07K7/54 ,  A61P29/00

摘要： Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts,






can inhibit TNFR1 and are expected to have utility as therapeutic agents, for example, for treating inflammatory bowel diseases, rheumatoid arthritis, junvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of inflammatory bowel diseases, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa, and for preparing pharmaceuticals for this purpose.